Postoperative delirium
Conditions
Interventions
Trial Group:Loading dose of dexmedetomidine 0.6 µg/kg administered 10 minutes before anesthesia induction, followed by continuous infusion at 0.5 µg/kg/h until 30 minutes before the end of surgery
other anesthetic regimens (sufentanil, propofol, cisatracurium, sevoflurane, remifentanil, etc.) were identical to those in the control group.
Control Group:Infusion of equivalent volume of normal saline (simulating dexmedetomidine administration protocol)
other anesthetic regimens (sufentanil, propofol, cisatracurium, sevoflurane, remifentanil, etc.) were identical to those in the trial group.
Sponsors
The Affiliated Hospital of North Sichuan Medical College, the First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Elderly patients (>= 65 years old) undergoing elective pulmonary surgery under general anesthesia; 2. American Society of Anesthesiology (ASA) physical status I–III; 3. Body mass index (BMI) 18–30 kg/m^2
Exclusion criteria
Exclusion criteria: 1. Preoperative cognitive impairment in Minimental State Examination (MMSE) (preoperative score <=17 (illiterate), <=20 (primary school), <=22 (secondary school), <=24 (high school and above); 2. History of cardiac surgery, cerebrovascular accident and alcohol abuse; 3. The presence of serious organic diseases, such as liver and kidney dysfunction; 4. Coagulation disorders; 5. Severe visual and hearing impairment, obstructing communication and communication disorders; 6. History of mental illness or long-term sedative or depressive medications, neurodegenerative diseases (Alzheimer's disease and Parkinson's disease); 7. Severe uncontrolled hypertension; 8. Admission to ICU due to severe postoperative complications; 9. Reoperation; 10. Loss to follow-up; 11. Patients with a history of acetylcholine use; 12. Severe respiratory diseases (respiratory failure, severe chronic obstructive pulmonary disease); 13. Patients with contraindications to dexmedetomidine; 14. Patients with severe subcutaneous emphysema, serious adverse events (such as intraoperative bleeding and severe hemodynamic fluctuations); 15. Emergency surgery; 16. Decision to withdraw from the study during the study period; 17. sinus bradycardia (heart rate (HR) <50 beats/min), sick sinus syndrome, or second degree atrioventricular block or greater.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of delirium within 3 days postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pre- and postoperative biological markers;Cognitive function;Depth of sedation;Heart rate (HR) and mean arterial pressure (MAP);Postoperative pain, anxiety, depression, and sleep status;Postoperative recovery status and complications;Pain, sleep, and recovery status; | — |
Countries
China
Contacts
Public ContactWen Wen, Xie YuBo
The Affiliated Hospital of North Sichuan Medical College, the First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed